| Drug General Information |
| Drug ID |
D0B0LC
|
| Former ID |
DNC004257
|
| Drug Name |
2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C15H13N3O
|
| Canonical SMILES |
C1=CC=NC(=C1)COC2=CC=C(C=C2)N3C=CN=C3
|
| InChI |
1S/C15H13N3O/c1-2-8-17-13(3-1)11-19-15-6-4-14(5-7-15)18-10-9-16-12-18/h1-10,12H,11H2
|
| InChIKey |
IMJROXJEYNKELD-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 2D6 |
Target Info |
Inhibitor |
[1]
|
|---|
| Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - cytochrome P450
|
|
Serotonergic synapsehsa00140:Steroid hormone biosynthesis
|
|
Linoleic acid metabolism
|
|
Retinol metabolism
|
|
Drug metabolism - other enzymes
|
|
Metabolic pathways
|
|
Bile secretion
|
|
Chemical carcinogenesis
|
|
PathWhiz Pathway
|
Caffeine Metabolism
|
|
Retinol Metabolism
|
|
Reactome
|
XenobioticsR-HSA-211981:Xenobiotics
|
|
Aflatoxin activation and detoxification
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Tamoxifen metabolism
|
|
Oxidation by Cytochrome P450
|
|
Vitamin D Receptor Pathway
|
|
Aripiprazole Metabolic Pathway
|
|
Fatty Acid Omega Oxidation
|
|
Codeine and Morphine MetabolismWP702:Metapathway biotransformation
|
|
Aflatoxin B1 metabolism
|
|
Estrogen metabolism
|
|
Benzo(a)pyrene metabolism
|
|
Tryptophan metabolism
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Farnesoid X Receptor Pathway
|
|
Felbamate Metabolism
|
|
Lidocaine metabolism
|
|
Nifedipine Activity
|
|
Colchicine Metabolic Pathway
|
|
Irinotecan Pathway
|
|
Drug Induction of Bile Acid Pathway
|
|
Codeine and Morphine Metabolism
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. |
|---|
